- Home
- AIFU vs CGTX Comparison
AIFU vs CGTX Comparison
Compare AIFU & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFU
- CGTX
- Stock Information
- Founded
- AIFU 1998
- CGTX 2007
- Country
- AIFU China
- CGTX United States
- Employees
- AIFU N/A
- CGTX N/A
- Industry
- AIFU
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- AIFU
- CGTX Health Care
- Exchange
- AIFU NYSE
- CGTX Nasdaq
- Market Cap
- AIFU 17.9M
- CGTX 17.9M
- IPO Year
- AIFU 2007
- CGTX 2021
- Fundamental
- Price
- AIFU $0.38
- CGTX $0.43
- Analyst Decision
- AIFU
- CGTX Strong Buy
- Analyst Count
- AIFU 0
- CGTX 6
- Target Price
- AIFU N/A
- CGTX $8.30
- AVG Volume (30 Days)
- AIFU 647.0K
- CGTX 2.8M
- Earning Date
- AIFU 03-19-2025
- CGTX 05-06-2025
- Dividend Yield
- AIFU N/A
- CGTX N/A
- EPS Growth
- AIFU N/A
- CGTX N/A
- EPS
- AIFU 0.38
- CGTX N/A
- Revenue
- AIFU $324,923,970.00
- CGTX N/A
- Revenue This Year
- AIFU N/A
- CGTX N/A
- Revenue Next Year
- AIFU $11.81
- CGTX N/A
- P/E Ratio
- AIFU $1.00
- CGTX N/A
- Revenue Growth
- AIFU N/A
- CGTX N/A
- 52 Week Low
- AIFU $0.29
- CGTX $0.34
- 52 Week High
- AIFU $6.59
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- AIFU N/A
- CGTX 27.35
- Support Level
- AIFU N/A
- CGTX $0.36
- Resistance Level
- AIFU N/A
- CGTX $0.45
- Average True Range (ATR)
- AIFU 0.00
- CGTX 0.05
- MACD
- AIFU 0.00
- CGTX -0.01
- Stochastic Oscillator
- AIFU 0.00
- CGTX 23.66
About AIFU FANHUA INC SPON ADS EACH REPR 20 ORD SHS
AIX Inc is a technology-driven financial services provider company in China. It is an intelligent platform that creates a supportive and collaborative environment and provides solutions that integrate technology, products, services, operations, capital, and professional support for individual agents and sales organizations. The group uses technology, AI, and data-driven insights, pioneering the financial services that are delivered, its transformation, and empowering industry development. It connects customers with financial institutions, investment opportunities, and service providers, offering insurance, wealth management, and other value-added services.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.